<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed the expression of the inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> survivin by immunocytochemistry in bone marrow cells from patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) to evaluate possible abnormalities in comparison with other myelodysplastic (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and myeloproliferative syndromes, and to investigate a possible correlation between survivin expression and altered <z:mpath ids='MPATH_3'>apoptosis</z:mpath> or proliferation, or relevant laboratory and clinical findings </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-four patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> [18 MDS-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and 16 <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>)-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>], 90 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 41 with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 19 with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> and 25 control subjects were studied </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> samples survivin was never detectable </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> survivin levels higher than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P &lt; 0.0001), but similar to those found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> were observed </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was significantly higher compared to <z:mpath ids='MPATH_458'>normal</z:mpath> controls and <z:hpo ids='HP_0000001'>all</z:hpo> other subtypes of <z:hpo ids='HP_0001909'>leukemias</z:hpo> (P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>Proliferation did not differ significantly in <z:mpath ids='MPATH_458'>normal</z:mpath> controls, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>; the lowest levels were observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> there was no correlation between survivin expression and blast cell percentage, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> or proliferation, FAB or WHO subgroup </plain></SENT>
<SENT sid="7" pm="."><plain>Proliferation was higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and tended to correlate with overall survival </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1333044" disease_type="Neoplastic Process" abbrv="">CMML-2</z:e> cases with higher survivin expression showed higher evolution rate and shorter survival </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> is characterized by high proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Survivin overexpression, by disrupting the balance between cell proliferation/differentiation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, may play an important role in its pathophysiology </plain></SENT>
<SENT sid="11" pm="."><plain>The detection of survivin-deregulated expression may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments </plain></SENT>
</text></document>